Study of lenalidomide and dexamethasone with or without pembrolizumab (MK-3475) in participants with newly diagnosed treatment naive multiple myeloma (MK-3475-185/KEYNOTE-185)
The purpose of this study is to compare the efficacy of lenalidomide and low dose dexamethasone with pembrolizumab (MK-3475) to that of lenalidomide and low dose dexamethasone without pembrolizumab in terms of progression-free survival (PFS) in participants with newly diagnosed and treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant (Auto-SCT).
Study Type: Interventional
Allocation: Randomised
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Phase III Study of Lenalidomide and Low-dose Dexamethasone With or Without Pembrolizumab (MK3475) in Newly Diagnosed and Treatment naïve Multiple Myeloma (KEYNOTE 185).
Arms:
Experimental: Pembrolizumab + lenalidomide + dexamethasone
Active Comparator: Lenalidomide + dexamethasone
| Category | Value |
|---|---|
| Date last updated at source | 2017-06-16 |
| Study type(s) | Interventional |
| Expected enrolment | 640 |
| Study start date | 2015-10-19 |
| Estimated primary completion date | 2021-07-31 |